U.S. study suggests that semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, may be useful to reduce alcohol consumption and craving in alcohol use disorder.
A low dosage of mefenamic acid, an anti-inflammatory drug, can potentially reduce a toxic compound in people with kidney disease, according to a study.
